385 related articles for article (PubMed ID: 10389946)
1. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the antigen-induced activation of rodent mast cells by putative Janus kinase 3 inhibitors WHI-P131 and WHI-P154 in a Janus kinase 3-independent manner.
Linwong W; Hirasawa N; Aoyama S; Hamada H; Saito T; Ohuchi K
Br J Pharmacol; 2005 Jul; 145(6):818-28. PubMed ID: 15852029
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of novel anticancer agents.
Uckun FM; Sudbeck EA; Mao C; Ghosh S; Liu XP; Vassilev AO; Navara CS; Narla RK
Curr Cancer Drug Targets; 2001 May; 1(1):59-71. PubMed ID: 12188892
[TBL] [Abstract][Full Text] [Related]
4. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
[TBL] [Abstract][Full Text] [Related]
5. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline.
Uckun FM; Ek O; Liu XP; Chen CL
Clin Cancer Res; 1999 Oct; 5(10):2954-62. PubMed ID: 10537365
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154).
Narla RK; Liu XP; Klis D; Uckun FM
Clin Cancer Res; 1998 Oct; 4(10):2463-71. PubMed ID: 9796979
[TBL] [Abstract][Full Text] [Related]
7. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
Mahajan S; Ghosh S; Sudbeck EA; Zheng Y; Downs S; Hupke M; Uckun FM
J Biol Chem; 1999 Apr; 274(14):9587-99. PubMed ID: 10092645
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in JAK3 kinase inhibitors.
Sudbeck EA; Uckun FM
IDrugs; 1999 Oct; 2(10):1026-30. PubMed ID: 16118711
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells.
Uckun FM; Dibirdik I; Qazi S; Yiv S
Arzneimittelforschung; 2010; 60(4):210-7. PubMed ID: 20486472
[TBL] [Abstract][Full Text] [Related]
10. In vivo pharmacokinetics and anti-anaphylactic activity of the novel mast cell inhibitor 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131).
Malavija R; Chen CL; Liu XP; Uckun FM
Am J Ther; 2001; 8(1):35-9. PubMed ID: 11304656
[TBL] [Abstract][Full Text] [Related]
11. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97).
Malaviya R; Chen CL; Navara C; Malaviya R; Liu XP; Keenan M; Waurzyniak B; Uckun FM
J Pharmacol Exp Ther; 2000 Dec; 295(3):912-26. PubMed ID: 11082424
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase 3 inhibitor WHI-P154 in macrophages activated by bacterial endotoxin: differential effects on the expression of iNOS, COX-2 and TNF-alpha.
Sareila O; Korhonen R; Kärpänniemi O; Nieminen R; Kankaanranta H; Moilanen E
Int Immunopharmacol; 2008 Jan; 8(1):100-8. PubMed ID: 18068105
[TBL] [Abstract][Full Text] [Related]
13. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis.
Malaviya R; Zhu D; Dibirdik I; Uckun FM
J Biol Chem; 1999 Sep; 274(38):27028-38. PubMed ID: 10480916
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
Ghosh S; Narla RK; Zheng Y; Liu XP; Jun X; Mao C; Sudbeck EA; Uckun FM
Anticancer Drug Des; 1999 Oct; 14(5):403-10. PubMed ID: 10766295
[TBL] [Abstract][Full Text] [Related]
15. EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line.
Kim S; Choi JH; Lim HI; Lee SK; Kim WW; Cho S; Kim JS; Kim JH; Choe JH; Nam SJ; Lee JE; Yang JH
Cell Signal; 2009 Jun; 21(6):892-8. PubMed ID: 19385051
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model.
Uckun FM; Roers BA; Waurzyniak B; Liu XP; Cetkovic-Cvrlje M
Blood; 2002 Jun; 99(11):4192-9. PubMed ID: 12010825
[TBL] [Abstract][Full Text] [Related]
17. CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation.
Uckun FM; Thoen J; Chen H; Sudbeck E; Mao C; Malaviya R; Liu XP; Chen CL
Drug Metab Dispos; 2002 Jan; 30(1):74-85. PubMed ID: 11744615
[TBL] [Abstract][Full Text] [Related]
18. Janus kinase 3 is expressed in erythrocytes, phosphorylated upon energy depletion and involved in the regulation of suicidal erythrocyte death.
Bhavsar SK; Gu S; Bobbala D; Lang F
Cell Physiol Biochem; 2011; 27(5):547-56. PubMed ID: 21691072
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma.
Amin HM; Medeiros LJ; Ma Y; Feretzaki M; Das P; Leventaki V; Rassidakis GZ; O'Connor SL; McDonnell TJ; Lai R
Oncogene; 2003 Aug; 22(35):5399-407. PubMed ID: 12934099
[TBL] [Abstract][Full Text] [Related]
20. Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1).
Cetkovic-Cvrlje M; Dragt AL; Uckun FM
Arzneimittelforschung; 2003; 53(9):648-54. PubMed ID: 14558439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
